ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-19A18322
Home | Market Reports | Health| Pharmacy
Global GLP 1 Targeted Peptide Weight Loss Drugs Market Research Report 2024
BUY CHAPTERS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

Code: QYRE-Auto-19A18322
Report
September 2025
Pages:117
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Astra Zeneca
Baxter Pharmaceutical
Zealand Pharma
Sanofi Aventis
Lexaria Bioscience
Chugai Pharmaceutical
Hikma Pharms
Amylin Pharmaceuticals
Orbis Biosciences
Intarcia Therapeutics
Qilu Pharmaceutical
Huadong Medicine
Jiuyuan Gene Engineering
Benemae Pharmaceutical
Nano Precision Medical
iX Biopharma
Nanexa AB
The General Hospital Corp
QuiaPEG Pharmaceuticals Ab

GLP-1 Targeted Peptide Weight Loss Drugs Market Size

The global market for GLP-1 Targeted Peptide Weight Loss Drugs was valued at US$ 60156 million in the year 2024 and is projected to reach a revised size of US$ 142157 million by 2031, growing at a CAGR of 12.0% during the forecast period.

GLP-1 Targeted Peptide Weight Loss Drugs Market

GLP-1 Targeted Peptide Weight Loss Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on GLP-1 Targeted Peptide Weight Loss Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
GLP-1 targeted peptide weight loss drugs are a class of medications that mimic the physiological effects of the incretin hormone GLP-1 (glucagon-like peptide-1) to regulate body weight and improve metabolic function. These drugs help reduce caloric intake, enhance insulin secretion, and delay gastric emptying, playing a key role in chronic weight management and metabolic control. In 2024, the global sales volume of GLP-1 targeted peptide weight loss drugs reached 614 million boxes, with an average price of 98 USD per box.
Market Overview
GLP-1 targeted peptide weight loss drugs have emerged as a significant category for managing obesity and related metabolic disorders. By mimicking endogenous incretin activity, these drugs regulate appetite, slow gastric emptying, and improve insulin sensitivity, gaining rapid adoption in the global market. Their clinical efficacy and safety in chronic weight management have been increasingly validated, positioning them as an essential option for obesity and type 2 diabetes treatment, with sustained growth in demand.
Regional Market Landscape
In 2024, North America accounted for 46% of the global market, Europe 23%, Asia-Pacific 19%, Latin America 7%, and the Middle East & Africa 5%. North America’s leading position is driven by high obesity prevalence, advanced healthcare infrastructure, and strong purchasing power. Europe benefits from supportive policies and chronic disease management demand, while the Asia-Pacific market is experiencing rapid growth due to lifestyle changes and rising obesity rates.
Major Manufacturers and Industry Competition
Key global manufacturers include Novo Nordisk, Eli Lilly, and Pfizer, competing intensively in R&D investment and product line development. Novo Nordisk holds a leading position with Semaglutide in the weight loss segment, while Eli Lilly has strategically developed Dulaglutide and Tirzepatide as multi-target GLP-1 therapies. Industry competition centers on new molecule design, dosage form optimization, and cross-regional market expansion strategies.
Technology Trends and Innovation Directions
Innovation focuses on long-acting peptide molecules, oral formulations, and multi-target combination therapies. Chemical modifications extend half-life and enhance bioavailability, while GLP-1/GIP dual agonists and GLP-1/glucagon receptor co-agonists are being explored to deliver more effective, personalized weight management solutions. Emerging delivery technologies, such as smart dosing systems and microneedle patches, aim to improve patient adherence.
Policy and Industry Development Drivers
Government attention to obesity prevention and chronic metabolic disease management is driving market development. Reimbursement coverage, accelerated drug approvals, and updated clinical guidelines are expanding the market. Industry growth is also fueled by rising global obesity rates, increased public health awareness, and heightened pharmaceutical investment in innovative drug development.
Future Outlook
The market is expected to continue expanding, with new long-acting peptides, oral formulations, and multi-target combination therapies as key growth drivers. North America and Europe will remain dominant markets, while Asia-Pacific will experience the fastest growth. Companies will maintain competitive advantages through innovative molecules, optimized delivery methods, and global market expansion, with regulatory policies and reimbursement support further strengthening market potential.

Report Scope

This report aims to provide a comprehensive presentation of the global market for GLP-1 Targeted Peptide Weight Loss Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Targeted Peptide Weight Loss Drugs.
The GLP-1 Targeted Peptide Weight Loss Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GLP-1 Targeted Peptide Weight Loss Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Targeted Peptide Weight Loss Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of GLP-1 Targeted Peptide Weight Loss Drugs Market Report

Report Metric Details
Report Name GLP-1 Targeted Peptide Weight Loss Drugs Market
Accounted market size in year US$ 60156 million
Forecasted market size in 2031 US$ 142157 million
CAGR 12.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Liraglutide
  • Semaglutide
  • Tirzepatide
  • Others
Segment by Application
  • Treatment of Type 2 Diabetes
  • Obesity and Weight Management
  • Cardiovascular Risk
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Eli Lilly, Astra Zeneca, Baxter Pharmaceutical, Nano Precision Medical, Zealand Pharma, Sanofi-Aventis, iX Biopharma, Lexaria Bioscience, Chugai Pharmaceutical, HIKMA PHARMS, Amylin Pharmaceuticals, Orbis Biosciences, Intarcia Therapeutics, Nanexa AB, The General Hospital Corp, QuiaPEG Pharmaceuticals Ab, Qilu Pharmaceutical, Huadong Medicine, Jiuyuan Gene Engineering, Benemae Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of GLP-1 Targeted Peptide Weight Loss Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is GLP-1 Targeted Peptide Weight Loss Drugs Market growing?

Ans: The GLP-1 Targeted Peptide Weight Loss Drugs Market witnessing a CAGR of 12.0% during the forecast period 2025-2031.

What is the GLP-1 Targeted Peptide Weight Loss Drugs Market size in 2031?

Ans: The GLP-1 Targeted Peptide Weight Loss Drugs Market size in 2031 will be US$ 142157 million.

Who are the main players in the GLP-1 Targeted Peptide Weight Loss Drugs Market report?

Ans: The main players in the GLP-1 Targeted Peptide Weight Loss Drugs Market are Novo Nordisk, Eli Lilly, Astra Zeneca, Baxter Pharmaceutical, Nano Precision Medical, Zealand Pharma, Sanofi-Aventis, iX Biopharma, Lexaria Bioscience, Chugai Pharmaceutical, HIKMA PHARMS, Amylin Pharmaceuticals, Orbis Biosciences, Intarcia Therapeutics, Nanexa AB, The General Hospital Corp, QuiaPEG Pharmaceuticals Ab, Qilu Pharmaceutical, Huadong Medicine, Jiuyuan Gene Engineering, Benemae Pharmaceutical

What are the Application segmentation covered in the GLP-1 Targeted Peptide Weight Loss Drugs Market report?

Ans: The Applications covered in the GLP-1 Targeted Peptide Weight Loss Drugs Market report are Treatment of Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Risk

What are the Type segmentation covered in the GLP-1 Targeted Peptide Weight Loss Drugs Market report?

Ans: The Types covered in the GLP-1 Targeted Peptide Weight Loss Drugs Market report are Liraglutide, Semaglutide, Tirzepatide, Others

1 GLP-1 Targeted Peptide Weight Loss Drugs Market Overview
1.1 Product Definition
1.2 GLP-1 Targeted Peptide Weight Loss Drugs by Type
1.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Liraglutide
1.2.3 Semaglutide
1.2.4 Tirzepatide
1.2.5 Others
1.3 GLP-1 Targeted Peptide Weight Loss Drugs by Application
1.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value by Application (2024 VS 2031)
1.3.2 Treatment of Type 2 Diabetes
1.3.3 Obesity and Weight Management
1.3.4 Cardiovascular Risk
1.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue 2020-2031
1.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales 2020-2031
1.4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 GLP-1 Targeted Peptide Weight Loss Drugs Market Competition by Manufacturers
2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of GLP-1 Targeted Peptide Weight Loss Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Date of Enter into This Industry
2.8 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Competitive Situation and Trends
2.8.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue
2.8.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Scenario by Region
3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2020-2031
3.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2020-2025
3.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2026-2031
3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2020-2031
3.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2020-2025
3.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2026-2031
3.4 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
3.4.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2031)
3.4.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
3.5.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2031)
3.5.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2031)
3.7.3 Latin America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2020-2031)
4.1.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2020-2025)
4.1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2026-2031)
4.1.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2020-2031)
4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2020-2031)
4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2020-2025)
4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2026-2031)
4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2020-2031)
4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2020-2031)
5.1.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2020-2025)
5.1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2026-2031)
5.1.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2020-2031)
5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2020-2031)
5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2020-2025)
5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2026-2031)
5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2020-2031)
5.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Astra Zeneca
6.3.1 Astra Zeneca Company Information
6.3.2 Astra Zeneca Description and Business Overview
6.3.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.3.5 Astra Zeneca Recent Developments/Updates
6.4 Baxter Pharmaceutical
6.4.1 Baxter Pharmaceutical Company Information
6.4.2 Baxter Pharmaceutical Description and Business Overview
6.4.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.4.5 Baxter Pharmaceutical Recent Developments/Updates
6.5 Nano Precision Medical
6.5.1 Nano Precision Medical Company Information
6.5.2 Nano Precision Medical Description and Business Overview
6.5.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.5.5 Nano Precision Medical Recent Developments/Updates
6.6 Zealand Pharma
6.6.1 Zealand Pharma Company Information
6.6.2 Zealand Pharma Description and Business Overview
6.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.6.5 Zealand Pharma Recent Developments/Updates
6.7 Sanofi-Aventis
6.7.1 Sanofi-Aventis Company Information
6.7.2 Sanofi-Aventis Description and Business Overview
6.7.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.7.5 Sanofi-Aventis Recent Developments/Updates
6.8 iX Biopharma
6.8.1 iX Biopharma Company Information
6.8.2 iX Biopharma Description and Business Overview
6.8.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.8.5 iX Biopharma Recent Developments/Updates
6.9 Lexaria Bioscience
6.9.1 Lexaria Bioscience Company Information
6.9.2 Lexaria Bioscience Description and Business Overview
6.9.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.9.5 Lexaria Bioscience Recent Developments/Updates
6.10 Chugai Pharmaceutical
6.10.1 Chugai Pharmaceutical Company Information
6.10.2 Chugai Pharmaceutical Description and Business Overview
6.10.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.10.5 Chugai Pharmaceutical Recent Developments/Updates
6.11 HIKMA PHARMS
6.11.1 HIKMA PHARMS Company Information
6.11.2 HIKMA PHARMS Description and Business Overview
6.11.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.11.5 HIKMA PHARMS Recent Developments/Updates
6.12 Amylin Pharmaceuticals
6.12.1 Amylin Pharmaceuticals Company Information
6.12.2 Amylin Pharmaceuticals Description and Business Overview
6.12.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.12.5 Amylin Pharmaceuticals Recent Developments/Updates
6.13 Orbis Biosciences
6.13.1 Orbis Biosciences Company Information
6.13.2 Orbis Biosciences Description and Business Overview
6.13.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.13.5 Orbis Biosciences Recent Developments/Updates
6.14 Intarcia Therapeutics
6.14.1 Intarcia Therapeutics Company Information
6.14.2 Intarcia Therapeutics Description and Business Overview
6.14.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.14.5 Intarcia Therapeutics Recent Developments/Updates
6.15 Nanexa AB
6.15.1 Nanexa AB Company Information
6.15.2 Nanexa AB Description and Business Overview
6.15.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.15.5 Nanexa AB Recent Developments/Updates
6.16 The General Hospital Corp
6.16.1 The General Hospital Corp Company Information
6.16.2 The General Hospital Corp Description and Business Overview
6.16.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.16.5 The General Hospital Corp Recent Developments/Updates
6.17 QuiaPEG Pharmaceuticals Ab
6.17.1 QuiaPEG Pharmaceuticals Ab Company Information
6.17.2 QuiaPEG Pharmaceuticals Ab Description and Business Overview
6.17.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.17.5 QuiaPEG Pharmaceuticals Ab Recent Developments/Updates
6.18 Qilu Pharmaceutical
6.18.1 Qilu Pharmaceutical Company Information
6.18.2 Qilu Pharmaceutical Description and Business Overview
6.18.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.18.5 Qilu Pharmaceutical Recent Developments/Updates
6.19 Huadong Medicine
6.19.1 Huadong Medicine Company Information
6.19.2 Huadong Medicine Description and Business Overview
6.19.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.19.5 Huadong Medicine Recent Developments/Updates
6.20 Jiuyuan Gene Engineering
6.20.1 Jiuyuan Gene Engineering Company Information
6.20.2 Jiuyuan Gene Engineering Description and Business Overview
6.20.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.20.5 Jiuyuan Gene Engineering Recent Developments/Updates
6.21 Benemae Pharmaceutical
6.21.1 Benemae Pharmaceutical Company Information
6.21.2 Benemae Pharmaceutical Description and Business Overview
6.21.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
6.21.5 Benemae Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Chain Analysis
7.2 GLP-1 Targeted Peptide Weight Loss Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process Analysis
7.4 GLP-1 Targeted Peptide Weight Loss Drugs Sales and Marketing
7.4.1 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels
7.4.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
7.5 GLP-1 Targeted Peptide Weight Loss Drugs Customer Analysis
8 GLP-1 Targeted Peptide Weight Loss Drugs Market Dynamics
8.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
8.2 GLP-1 Targeted Peptide Weight Loss Drugs Market Drivers
8.3 GLP-1 Targeted Peptide Weight Loss Drugs Market Challenges
8.4 GLP-1 Targeted Peptide Weight Loss Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
Astra Zeneca
Baxter Pharmaceutical
Zealand Pharma
Sanofi Aventis
Lexaria Bioscience
Chugai Pharmaceutical
Hikma Pharms
Amylin Pharmaceuticals
Orbis Biosciences
Intarcia Therapeutics
Qilu Pharmaceutical
Huadong Medicine
Jiuyuan Gene Engineering
Benemae Pharmaceutical
Nano Precision Medical
iX Biopharma
Nanexa AB
The General Hospital Corp
QuiaPEG Pharmaceuticals Ab
List of Tables
 Table 1. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of GLP-1 Targeted Peptide Weight Loss Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global GLP-1 Targeted Peptide Weight Loss Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Targeted Peptide Weight Loss Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Eli Lilly Company Information
 Table 76. Eli Lilly Description and Business Overview
 Table 77. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 79. Eli Lilly Recent Developments/Updates
 Table 80. Astra Zeneca Company Information
 Table 81. Astra Zeneca Description and Business Overview
 Table 82. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 84. Astra Zeneca Recent Developments/Updates
 Table 85. Baxter Pharmaceutical Company Information
 Table 86. Baxter Pharmaceutical Description and Business Overview
 Table 87. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 89. Baxter Pharmaceutical Recent Developments/Updates
 Table 90. Nano Precision Medical Company Information
 Table 91. Nano Precision Medical Description and Business Overview
 Table 92. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 94. Nano Precision Medical Recent Developments/Updates
 Table 95. Zealand Pharma Company Information
 Table 96. Zealand Pharma Description and Business Overview
 Table 97. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 99. Zealand Pharma Recent Developments/Updates
 Table 100. Sanofi-Aventis Company Information
 Table 101. Sanofi-Aventis Description and Business Overview
 Table 102. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 104. Sanofi-Aventis Recent Developments/Updates
 Table 105. iX Biopharma Company Information
 Table 106. iX Biopharma Description and Business Overview
 Table 107. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 109. iX Biopharma Recent Developments/Updates
 Table 110. Lexaria Bioscience Company Information
 Table 111. Lexaria Bioscience Description and Business Overview
 Table 112. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 114. Lexaria Bioscience Recent Developments/Updates
 Table 115. Chugai Pharmaceutical Company Information
 Table 116. Chugai Pharmaceutical Description and Business Overview
 Table 117. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 119. Chugai Pharmaceutical Recent Developments/Updates
 Table 120. HIKMA PHARMS Company Information
 Table 121. HIKMA PHARMS Description and Business Overview
 Table 122. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 124. HIKMA PHARMS Recent Developments/Updates
 Table 125. Amylin Pharmaceuticals Company Information
 Table 126. Amylin Pharmaceuticals Description and Business Overview
 Table 127. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 129. Amylin Pharmaceuticals Recent Developments/Updates
 Table 130. Orbis Biosciences Company Information
 Table 131. Orbis Biosciences Description and Business Overview
 Table 132. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 134. Orbis Biosciences Recent Developments/Updates
 Table 135. Intarcia Therapeutics Company Information
 Table 136. Intarcia Therapeutics Description and Business Overview
 Table 137. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 139. Intarcia Therapeutics Recent Developments/Updates
 Table 140. Nanexa AB Company Information
 Table 141. Nanexa AB Description and Business Overview
 Table 142. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 144. Nanexa AB Recent Developments/Updates
 Table 145. The General Hospital Corp Company Information
 Table 146. The General Hospital Corp Description and Business Overview
 Table 147. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 149. The General Hospital Corp Recent Developments/Updates
 Table 150. QuiaPEG Pharmaceuticals Ab Company Information
 Table 151. QuiaPEG Pharmaceuticals Ab Description and Business Overview
 Table 152. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 154. QuiaPEG Pharmaceuticals Ab Recent Developments/Updates
 Table 155. Qilu Pharmaceutical Company Information
 Table 156. Qilu Pharmaceutical Description and Business Overview
 Table 157. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 159. Qilu Pharmaceutical Recent Developments/Updates
 Table 160. Huadong Medicine Company Information
 Table 161. Huadong Medicine Description and Business Overview
 Table 162. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 164. Huadong Medicine Recent Developments/Updates
 Table 165. Jiuyuan Gene Engineering Company Information
 Table 166. Jiuyuan Gene Engineering Description and Business Overview
 Table 167. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 169. Jiuyuan Gene Engineering Recent Developments/Updates
 Table 170. Benemae Pharmaceutical Company Information
 Table 171. Benemae Pharmaceutical Description and Business Overview
 Table 172. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 173. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product
 Table 174. Benemae Pharmaceutical Recent Developments/Updates
 Table 175. Key Raw Materials Lists
 Table 176. Raw Materials Key Suppliers Lists
 Table 177. GLP-1 Targeted Peptide Weight Loss Drugs Distributors List
 Table 178. GLP-1 Targeted Peptide Weight Loss Drugs Customers List
 Table 179. GLP-1 Targeted Peptide Weight Loss Drugs Market Trends
 Table 180. GLP-1 Targeted Peptide Weight Loss Drugs Market Drivers
 Table 181. GLP-1 Targeted Peptide Weight Loss Drugs Market Challenges
 Table 182. GLP-1 Targeted Peptide Weight Loss Drugs Market Restraints
 Table 183. Research Programs/Design for This Report
 Table 184. Key Data Information from Secondary Sources
 Table 185. Key Data Information from Primary Sources
 Table 186. Authors List of This Report


List of Figures
 Figure 1. Product Picture of GLP-1 Targeted Peptide Weight Loss Drugs
 Figure 2. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Type: 2024 & 2031
 Figure 4. Liraglutide Product Picture
 Figure 5. Semaglutide Product Picture
 Figure 6. Tirzepatide Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Application: 2024 & 2031
 Figure 10. Treatment of Type 2 Diabetes
 Figure 11. Obesity and Weight Management
 Figure 12. Cardiovascular Risk
 Figure 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (2020-2031) & (US$ Million)
 Figure 15. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2020-2031) & (K Units)
 Figure 16. Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 17. GLP-1 Targeted Peptide Weight Loss Drugs Report Years Considered
 Figure 18. GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Manufacturers in 2024
 Figure 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest GLP-1 Targeted Peptide Weight Loss Drugs Players: Market Share by Revenue in GLP-1 Targeted Peptide Weight Loss Drugs in 2024
 Figure 21. GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2020-2031)
 Figure 24. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2020-2031)
 Figure 25. United States GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2020-2031)
 Figure 28. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2020-2031)
 Figure 29. Germany GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2020-2031)
 Figure 36. China GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Colombia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of GLP-1 Targeted Peptide Weight Loss Drugs by Type (2020-2031)
 Figure 55. Global Revenue Market Share of GLP-1 Targeted Peptide Weight Loss Drugs by Type (2020-2031)
 Figure 56. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of GLP-1 Targeted Peptide Weight Loss Drugs by Application (2020-2031)
 Figure 58. Global Revenue Market Share of GLP-1 Targeted Peptide Weight Loss Drugs by Application (2020-2031)
 Figure 59. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 60. GLP-1 Targeted Peptide Weight Loss Drugs Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions